HCW Biologics Inc. (NASDAQ:HCWB) Sees Large Decline in Short Interest

HCW Biologics Inc. (NASDAQ:HCWB) saw a significant decline in short interest in the month of September. As of September 15th, there was short interest totaling 9,274 shares, a decline of 72.8% from the August 31st total of 34,136 shares. Approximately 0.6% of the company’s shares are sold short. Based on an average trading volume of 414,337 shares, the days-to-cover ratio is currently 0.0 days.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of HCW Biologics in a report on Friday, July 17th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $30.00.

HCW Biologics Price Performance

NASDAQ HCWB traded down $0.06 during mid-day trading on Friday, reaching $1.93. 416,919 shares of the stock were exchanged, compared to its average volume of 942,148. HCW Biologics has a one year low of $1.50 and a one year high of $29.28. The stock has a 50 day simple moving average of $2.72 and a 200-day simple moving average of $4.36. The stock has a market cap of $3.54 million, a P/E ratio of -0.07 and a beta of 2.37.

HCW Biologics (NASDAQ:HCWB) last released its earnings results on Friday, August 14th. The company reported ($11.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.98) by ($9.60). HCW Biologics had a negative net margin of 83.03% and a negative return on equity of 262.33%. The firm had revenue of $0.14 million during the quarter, compared to analyst estimates of $0.14 million.

HCW Biologics Company Profile

HCW Biologics Inc is a clinical-stage biotechnology company focused on developing immunotherapies for diseases associated with chronic, low-grade inflammation, including cancer and age-related conditions. The company’s approach is designed to restore immune balance by reducing harmful inflammation while enhancing the body’s ability to generate an effective immune response.

HCW Biologics uses its proprietary Tissue-based Optimized Biologics Immunotherapy (TOBI™) platform to create engineered fusion-protein therapeutics.